EAP-derived monoclonal antibodies for phenotyping guinea PIG immune cells.
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93020C00024
- Awardee
-
Silver Lake Research Corporation UEI C9FZMJCTQFP4
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $600,000
Award facts
- Opportunity
-
- PHS202001 Solicitation number
- Contract value 100% obligated
- $600,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 5 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Irwindale, CA, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $600,000 |
About this award
This $600,000 firm fixed price contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Silver Lake Research Corporation, doing business as Silver Lake Research Corp., for EAP-derived monoclonal antibodies for phenotyping guinea pig immune cells under Phase I of the Small Business Innovation Research (SBIR) program for fiscal year 2020. As a total small business set-aside, the contract supports Silver Lake's research and development efforts to deliver monoclonal antibodies for use in characterizing immune cells in guinea pigs. Place of performance is in Irwindale, California, with a period of performance from July 2020 through December 2022. The contract advances the National Institute of Allergy and Infectious Diseases' mission to conduct and support research on the causes, treatments, and prevention of allergy and infectious diseases.
Quick answers
Who was awarded contract 75N93020C00024?
75N93020C00024 was awarded to Silver Lake Research Corporation by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 1, 2020.
How much is contract 75N93020C00024 worth?
The government has obligated $600,000 on 75N93020C00024.
Was contract 75N93020C00024 competed?
The extent of competition for 75N93020C00024 was full and open competition after exclusion of sources. The government received 5 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award